Carfilzomib prescribing patterns and outcomes for relapsed or refractory multiple myeloma: a real-world analysis - Takeaways - MDSpire

Carfilzomib prescribing patterns and outcomes for relapsed or refractory multiple myeloma: a real-world analysis

  • By

  • Sharlene Dong

  • Rahul Banerjee

  • Adeel M. Khan

  • Mengru Wang

  • Xiaoliang Wang

  • Anosheh Afghahi

  • Aimaz Afrough

  • Murali Janakiram

  • Bo Wang

  • Andrew J. Cowan

  • Adam S. Sperling

  • Larry D. Anderson

  • S. Vincent Rajkumar

  • Gurbakhash Kaur

  • March 28, 2025

  • 0 min

Share

  • 1

    Carfilzomib is a proteasome inhibitor used for treating relapsed or refractory multiple myeloma, often combined with dexamethasone.

  • 2

    Clinical studies show carfilzomib improves progression-free survival and overall survival compared to bortezomib in relapsed/refractory multiple myeloma.

  • 3

    Dosing schedules for carfilzomib vary significantly, with studies using doses from 20 mg/m² to 70 mg/m² and different administration frequencies.

  • 4

    Real-world data from 280 cancer clinics in the US was analyzed to assess carfilzomib prescribing patterns and clinical outcomes in multiple myeloma.

  • 5

    There is no consensus on the optimal carfilzomib dosing schedule, highlighting the need for further research to minimize toxicity and improve patient outcomes.

Original Source(s)

Carfilzomib prescribing patterns and outcomes for relapsed or refractory multiple myeloma: a real-world analysis

  • by Sharlene Dong, Rahul Banerjee, Adeel M. Khan, Mengru Wang, Xiaoliang Wang, Anosheh Afghahi, Aimaz Afrough, Murali Janakiram, Bo Wang, Andrew J. Cowan, Adam S. Sperling, Larry D. Anderson, S. Vincent Rajkumar, Gurbakhash Kaur

  • March 28, 2025

Related Content

Bridging therapy before CAR-T for multiple myeloma: a survey from the CMWP and CTIWP of the EBMT

Treatment Intensity in the Frontline Setting for Transplant-Ineligible Patients With Multiple Myeloma

The management of newly diagnosed transplant-ineligible multiple myeloma remains challenging, in part due to the complexity of treatment decisions for frail patients. Recent subgroup analyses provide insight into whether quadruplet therapy may offer advantages over triplet therapy in this population.

Dana-Farber Team Develops Open-Access Predictive Tool to Improve Monitoring of Smoldering Multiple Myeloma

The tool, called PANGEA-SMM, outperforms existing predictive tools by more accurately determining when smoldering multiple myeloma is progressing and requires treatment. The free online tool can be used immediately to monitor patients.

  • by

  • March 24, 2026

  • 5 min